NovoCure Limited Stock Börse Stuttgart
Stocks
038
JE00BYSS4X48
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.15 EUR | -21.99% |
|
-20.51% | +9.51% |
| 06-18 | Top Midday Decliners | MT |
| 06-18 | Novocure Announces Topline Data from the Phase 3 Trident Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma | CI |
| Market Cap | 1.65B 1.44B 1.34B 1.25B 2.34B 156B 2.36B 15.84B 6.14B 76.82B 6.21B 6.07B 267B | P/E 2026 * |
-8.96x | P/E 2027 * | -12x |
|---|---|---|---|---|---|
| Enterprise Value | 1.43B 1.25B 1.16B 1.08B 2.03B 135B 2.04B 13.71B 5.31B 66.51B 5.37B 5.26B 231B | EV / Sales 2026 * |
2.03x | EV / Sales 2027 * | 2.14x |
| Free-Float |
89.99% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: NovoCure Limited
| 1 week | -20.51% | ||
| Current month | -16.72% | ||
| 1 month | -17.29% | ||
| 3 months | +16.38% | ||
| 6 months | +15.38% | ||
| Current year | +9.51% |
| 1 week | 12.15 |  | 15.7 |
| 1 month | 12.15 | | 15.9 |
| 3 years | 8.26 | | 41.11 |
| 5 years | 8.26 | | 191.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Leonard
CEO | Chief Executive Officer | 46 | 2025-11-30 |
| Director of Finance/CFO | 52 | 2024-12-31 | |
Moshe Giladi
CTO | Chief Tech/Sci/R&D Officer | - | 2023-01-16 |
| Director | Title | Age | Since |
|---|---|---|---|
Asaf Danziger
BRD | Director/Board Member | 58 | 2011-12-31 |
Bill Doyle
CHM | Chairman | 63 | 2008-12-31 |
Kin Yip Leung
BRD | Director/Board Member | 64 | 2011-08-04 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -21.99% | -20.51% | -14.80% | -69.75% | 1.65B | |
| +0.33% | -0.47% | +23.49% | -6.09% | 12.48B | |
| -1.61% | -3.93% | +52.52% | +24.03% | 5.75B | |
| +0.23% | -1.20% | +6.10% | +0.65% | 5.51B | |
| +4.23% | -2.57% | - | - | 4.15B | |
| -2.42% | -6.52% | -30.18% | +11.61% | 4B | |
| -2.06% | -4.78% | -29.65% | -28.86% | 3.65B | |
| +3.49% | +6.69% | +56.28% | +255.43% | 1.84B | |
| -0.37% | -1.59% | +60.47% | -7.57% | 1.53B | |
| +1.96% | -2.15% | -13.95% | -50.43% | 1.28B | |
| Average | +0.42% | -0.97% | +12.25% | +14.34% | 4.46B | |
| Weighted average by Cap. | +0.12% | -1.40% | +14.68% | +7.57% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 704M 614M 568M 533M 998M 66.39B 1B 6.74B 2.61B 32.69B 2.64B 2.59B 114B | 774M 675M 625M 586M 1.1B 73B 1.11B 7.41B 2.87B 35.95B 2.91B 2.84B 125B |
| Net income | -183M -160M -148M -139M -260M -17.29B -262M -1.76B -680M -8.51B -688M -673M -29.59B | -136M -119M -110M -103M -193M -12.82B -194M -1.3B -504M -6.31B -510M -499M -21.94B |
| Net Debt | -222M -194M -179M -168M -315M -20.94B -317M -2.13B -824M -10.31B -833M -815M -35.84B | - |
| Date | Price | Change |
|---|---|---|
| 26-06-19 | 12.15 € | -21.99% |
| 26-06-18 | 15.58 € | +0.71% |
| 26-06-17 | 15.46 € | +2.49% |
| 26-06-16 | 15.09 € | -0.79% |
| 26-06-15 | 15.21 € | -0.49% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NVCR Stock
- 038 Stock
Select your edition
All financial news and data tailored to specific country editions
